Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jul 29;4(7):12827-12832.
doi: 10.1021/acsomega.9b01678. eCollection 2019 Jul 31.

NMR Assays for Estimating the O-Acetyl Content of Meningococcal Polysaccharide Serogroup A in Quadrivalent Conjugate Vaccine Formulation

Silvia Martini  1 , Marianna Aggravi  1 , Simona Cianetti  1 , William Egan  1 , Malte Meppen  1 , Alessio Moriconi  1 , Luca Simeone  1 , Francesco Berti  1
Affiliations

NMR Assays for Estimating the O-Acetyl Content of Meningococcal Polysaccharide Serogroup A in Quadrivalent Conjugate Vaccine Formulation

Silvia Martini et al. ACS Omega. .

Erratum in

Abstract

The use of multivalent glycoconjugate vaccines has dramatically contributed to reduce the incidence of meningococcal infectious disease. The advanced structural characterization of polysaccharide conjugates leads to enhancements in the quality and control of the products. Here, we report a novel nuclear magnetic resonance (NMR) method to confirm the identity and structural conformity (e.g., O-acetyl content) of saccharide antigens that comprise a licensed tetravalent meningococcal serogroups A, C, W, and Y vaccine. For the first time, the NMR methodology is applied on a formulation (licensed vaccine) containing a large excess of excipient (i.e., sucrose) without analytical sample pretreatment. This work confirms the applicability of a rapid and easy NMR assay on a multivalent conjugate vaccine, which might be extended to other combination vaccines that are already licensed or in clinical development.

PubMed Disclaimer

Conflict of interest statement

The authors declare the following competing financial interest(s): All the authors are employees of the GSK companies. Francesco Berti (corresponding author) is owner of patents on related topics. This study was sponsored by GSK Biologicals SA.

Figures

Figure 1
Figure 1
Structural representation of MenA-, MenC, MenW, and MenY-CRM197 conjugates (R: H, acetyl). The protons used as the label for the identity test of each antigen are highlighted in blue.
Figure 2
Figure 2
1H NMR spectra of the quadrivalent licensed Menveo vaccine. Labels to facilitate the peak assignment for MenA, MenC, MenW, and MenY antigens are shown.
Figure 3
Figure 3
(a) 1H–31P HMBC spectrum of the MenA-CRM197 sample; (b) 1H NMR spectral window where H1MAnAc of MenA-antigen resonates. The vertical bars show the integral regions identified for measuring the OAc and non OAc forms. Labels to facilitate the peak assignment are shown.
Figure 4
Figure 4
1H spectrum of the monovalent MenA-CRM197 sample. Labels to facilitate the peak assignment are shown.
See this image and copyright information in PMC

References

    1. Berti F.Multivalent meningococcal conjugate vaccines: chemical conjugation strategies used for the preparation of vaccines licensed or in clinical trials. In Carbohydrate-Based Vaccines: From Concept to Clinic, ACS Symposium Series, 2018; Vol. 1290, chapter 6, pp 123–137.
    1. Chen W. H.; Neuzil K. M.; Boyce C. R.; Pasetti M. F.; Reymann M. K.; Martellet L.; Hosken N.; LaForce F. M.; Dhere R. M.; Pisal S. S.; Chaudhari A.; Kulkarni P. S.; Borrow R.; Findlow H.; Brown V.; McDonough M. L.; Dally L.; Alderson M. R. Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine containing serogroups A, C, Y, W, and X in healthy adults: a phase 1, single-centre, double-blind, randomised, controlled study. Lancet Infect. Dis. 2018, 18, 1088–1096. 10.1016/s1473-3099(18)30400-6. - DOI - PubMed
    1. Jones C. Vaccines based on the cell surface carbohydrates of pathogenic bacteria. An. Acad. Bras. Cienc. 2005, 77, 293–324. 10.1590/s0001-37652005000200009. - DOI - PubMed
    1. Jones C. NMR assays for carbohydrate-based vaccines. J. Pharm. Biomed. Anal. 2005, 38, 840–850. 10.1016/j.jpba.2005.01.044. - DOI - PubMed
    1. Berti F.; Ravenscroft N. Characterization of carbohydrate vaccines by NMR spectroscopy. Methods Mol. Biol. 2015, 1331, 189–209. 10.1007/978-1-4939-2874-3_12. - DOI - PubMed

LinkOut - more resources